DISCLAIMER — Not financial advice. Educational content only, not an offer or solicitation to buy or sell any security. Biotech and small/mid-cap stocks are highly speculative and volatile and can result in a partial or total loss of capital. Do your own research and consult a licensed advisor where appropriate. / Contenuti a solo scopo informativo e didattico, non costituiscono consulenza finanziaria né offerta o sollecitazione al pubblico risparmio ai sensi delle normative CONSOB e SEC. Le azioni biotech e le small/mid cap sono strumenti altamente speculativi e volatili e possono comportare la perdita parziale o totale del capitale investito. Si raccomanda di effettuare sempre le proprie ricerche e, se necessario, di rivolgersi a un consulente abilitato.
Merlintrader Trading Pub
Biotech catalyst news and analysis. FDA PDUFA tracker
Category AGIO
http://www.agios.com/
Agios Pharmaceuticals ( $AGIO ): the story did not end with the sickle-cell disappointment
Agios is not the same story it was one year ago, and it is not even the same story it was right after the market reacted badly to the November 2025 RISE UP data. The cleanest way to frame the company today is not as a single-product binary biotech and not as a fully de-risked rare-disease compounder either. It sits somewhere in the middle. There is now a real commercial base, a very strong balance sheet by biotech standards, a broader geographic footprint for mitapivat in thalassemia, and a reopened regulatory path in sickle cell disease that most investors had at least partially discounted after the mixed Phase 3 readout.
AGIO Agios Pharmaceuticals Inc
A year ago, Agios was still mostly a “promise stock”: one approved niche drug for pyruvate kinase deficiency and a lot of hope around sickle cell disease. Today the picture is more complex but also more concrete: mitapivat now has two U.S. approvals, a full rare-disease haematology franchise is forming, and 2026 has a surprisingly busy catalyst map.
AGIO Agios Pharmaceuticals
From FDA approval of AQVESME in alpha/beta-thalassemia to the next catalysts in sickle cell and MDS: a filings-based look at where Agios really stands now.
AGIO BCRX MIST December 7-13, 2025: Three Biotech PDUFA Catalysts – Complete Analysis
AGIO, BCRX, MIST: December 2025 PDUFA Deep Dive | Analyst Targets & Timeline
AGIO
AGIO "From Crisis to Recovery: How Dec 7 + Jan 22 PDUFA Decisions Could Drive +80–120% Upside"
$AGIO
Agios Pharmaceuticals è un biotech specializzato nel trattamento di rare malattie ematologiche attraverso l'attivazione della piruvato chinasi. Il suo principale asset PYRUKYND (mitapivat) rappresenta una breakthrough therapy per thalassemia e sickle cell disease, con catalizzatori critici imminenti nel Q4 2025.
$AGIO
AGIO anche questa continua ad essere interessante in vista del PDUFA di dicembre; non ha un prezzo basso , ma ha solo 58M di azioni. Può fare una bella strada nel prossimo mese.
$AGIO
Come sempre , la prudenza è d'obbligo. leggete bene la storia, rispettate il grafico ed il trend (salvo eventi macro imprevedibili tipo Trump che spara sciocchezze) .
Anche se non è una small cap ha buone potenzialità.
